With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

An all-female research group from the University of the Philippines found that a compound derived from Philippine blue sponge ...

A Massachusetts company is transforming the way breast cancer is detected in real time. Newton-based Lumicell launched its ...